Publications by authors named "J R Masuda"

: Routine activated partial thromboplastin time (APTT) and prothrombin time (PT) measurements do not indicate hypercoagulability in patients with acute myocardial infarction (AMI) and acute cerebral infarction (ACI). : Hypercoagulability in patients with AMI or ACI was evaluated using a clot waveform analysis of the APTT or a small amount of tissue factor activation assay (sTF/FIXa). In the CWA, the derivative peak time (DPT), height (DPH), width (DPW), and area the under the curve (AUC) were evaluated.

View Article and Find Full Text PDF

Background: Neoadjuvant pembrolizumab plus chemotherapy and adjuvant pembrolizumab have been established as the optimal systemic therapies for patients with early stage triple-negative breast cancer (TNBC); however, their efficacy and feasibility in the Japanese population remain unexplored.

Methods: This study included patients with early stage TNBC or low estrogen receptor (ER) positivity (1-9%) with human epidermal growth factor receptor type 2- (HER2-) negative breast cancer who received neoadjuvant pembrolizumab plus chemotherapy from October 2022 at Cancer Institute Hospital of Japanese Foundation for Cancer Research. Information regarding clinicopathological features, systemic therapy, treatment outcomes, and adverse events of patients who underwent surgery by February 2024 was retrospectively collected.

View Article and Find Full Text PDF

Prenatal exposures to environmental toxicants can adversely affect fetal and child development and lead to increased risk of chronic disease. While regulatory action is essential to reduce sources of environmental toxicants, prenatal care presents an opportunity to educate, mobilize, and support prospective parents to reduce exposures to such hazards. As the first phase of an interdisciplinary research collaboration to inform the development of prenatal environmental health education strategy in Canada, we surveyed reproductive-aged female individuals.

View Article and Find Full Text PDF
Article Synopsis
  • * The study found that sCLEC-2 levels were significantly elevated in patients with thrombotic or infectious diseases, especially in microvascular thrombosis (MVT), but the relationships between sCLEC-2, platelet count, and D-dimer were weak.
  • * ROC analysis indicates that combinations of sCLEC-2 with platelet count and D-dimer can effectively differentiate between thrombotic diseases like MVT and non-thrombotic conditions, making sCLEC-2 a
View Article and Find Full Text PDF
Article Synopsis
  • * The study found that infliximab had the longest median treatment duration at 33.6 months, while brodalumab had the shortest at 9.7 months, with 1-year treatment survival rates being highest for guselkumab (83%) and lowest for brodalumab (45%).
  • * Key factors influencing treatment persistence included male sex and specific psoriasis diagnostic codes, with bio-experienced patients showing slightly longer treatment lengths compared to bio-naïve patients.
View Article and Find Full Text PDF